Literature DB >> 17135344

Down-regulation of intestinal drug transporters in chronic renal failure in rats.

Judith Naud1, Josée Michaud, Caroline Boisvert, Karine Desbiens, Francois A Leblond, Andrew Mitchell, Christine Jones, Alain Bonnardeaux, Vincent Pichette.   

Abstract

Chronic renal failure (CRF) is associated with an increased bioavailability of drugs by a poorly understood mechanism. One hypothesis is a reduction in the elimination of drugs by the intestine, i.e., drug elimination mediated by protein membrane transporters such as P-glycoprotein (Pgp) and multidrug-resistance-related protein (MRP) 2. The present study aimed to investigate the repercussions of CRF on intestinal transporters involved in drug absorption [organic anion-transportingpolypeptide (Oatp)] and those implicated in drug extrusion (Pgp and MRP2). Pgp, MRP2, MRP3, Oatp2, and Oatp3 protein expression and Pgp, MRP2, and Oatp3 mRNA expression were assessed in the intestine of CRF (induced by five-sixth nephrectomy) and control rats. Pgp and MRP2 activities were measured using the everted gut technique. Rat enterocytes and Caco-2 cells were incubated with sera from control and CRF rats to characterize the mechanism of transporters' down-regulation. Protein expression of Pgp, MRP2, and MRP3 were reduced by more than 40% (p < 0.01) in CRF rats, whereas Oatp2 and Oatp3 expression remained unchanged. There was no difference in the mRNA levels assessed by real-time polymerase chain reaction. Pgp and MRP2 activities were decreased by 30 and 25%, respectively, in CRF rats compared with control (p < 0.05). Uremic sera induced a reduction in protein expression and in activity of drug transporters compared with control sera. Our results demonstrate that CRF in rats is associated with a decrease in intestinal Pgp and MRP2 protein expression and function secondarily to serum uremic factors. This reduction could explain the increased bioavailability of drugs in CRF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135344     DOI: 10.1124/jpet.106.112631

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

Review 2.  Drug Transporters and Na+/H+ Exchange Regulatory Factor PSD-95/Drosophila Discs Large/ZO-1 Proteins.

Authors:  Dustin R Walsh; Thomas D Nolin; Peter A Friedman
Journal:  Pharmacol Rev       Date:  2015-07       Impact factor: 25.468

Review 3.  The organic anion transporter (OAT) family: a systems biology perspective.

Authors:  Sanjay K Nigam; Kevin T Bush; Gleb Martovetsky; Sun-Young Ahn; Henry C Liu; Erin Richard; Vibha Bhatnagar; Wei Wu
Journal:  Physiol Rev       Date:  2015-01       Impact factor: 37.312

4.  Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.

Authors:  Hiroyuki Sayama; Hiroaki Takubo; Hiroshi Komura; Motohiro Kogayu; Masahiro Iwaki
Journal:  AAPS J       Date:  2014-06-11       Impact factor: 4.009

Review 5.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

6.  A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients.

Authors:  Daniel Moj; Hugo Maas; André Schaeftlein; Nina Hanke; José David Gómez-Mantilla; Thorsten Lehr
Journal:  Clin Pharmacokinet       Date:  2019-12       Impact factor: 6.447

7.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

8.  Decreased lithium disposition to cerebrospinal fluid in rats with glycerol-induced acute renal failure.

Authors:  Rie Sakae; Atsuko Ishikawa; Tomoko Niso; Yukiko Komori; Tetsuya Aiba; Hiromu Kawasaki; Yuji Kurosaki
Journal:  Pharm Res       Date:  2008-06-26       Impact factor: 4.200

9.  ESRD impairs nonrenal clearance of fexofenadine but not midazolam.

Authors:  Thomas D Nolin; Reginald F Frye; Phuong Le; Hooman Sadr; Judith Naud; Francois A Leblond; Vincent Pichette; Jonathan Himmelfarb
Journal:  J Am Soc Nephrol       Date:  2009-08-20       Impact factor: 10.121

10.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.